At least one preventive or therapeutic agent selected from the group consisting of biliary tract cancer, skin cancer, esophageal cancer, and head and neck squamous cell carcinoma.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- DOSHISHA UNIVERSITY
- Filing Date
- 2021-10-26
- Publication Date
- 2026-06-25
AI Technical Summary
【0011】 本発明によれば、胆道がん、皮膚がん、食道がん、及び頭頚部扁平上皮がんからなる群より選択される少なくとも1種の予防又は治療剤を提供することができる。
Smart Images
Figure 0007880115000001 
Figure 0007880115000002 
Figure 0007880115000003
Abstract
Claims
1. A prophylactic or therapeutic agent containing F12511, selected from the group consisting of biliary tract cancer, skin cancer, esophageal cancer, and head and neck squamous cell carcinoma.
2. An agent for the prevention or treatment of esophageal cancer, comprising avasimibe.
3. The preventive or therapeutic agent according to claim 1, which is a preventive or therapeutic agent for bile duct cancer or malignant melanoma.
4. A prophylactic or therapeutic agent according to any one of claims 1 to 3, which is a cell cycle arresting anticancer agent.
5. A cell proliferation inhibitor containing F12511, selected from the group consisting of biliary tract cancer cells, skin cancer cells, esophageal cancer cells, and head and neck squamous cell carcinoma cells.
6. An inhibitor of cell proliferation of esophageal cancer cells, comprising avasimibe.